Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults
NCT03036930Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, human papillomavirus-related carcinoma, sponsored by National Cancer Institute. Started Jun 2017; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionhuman papillomavirus-related carcinoma
Beyond the preview
Go deeper on NCT03036930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03036930.